Latest News and Press Releases
Want to stay updated on the latest news?
-
MECHELEN, Belgium, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) announces the initiation of the first Phase 1 study with GLPG1837. This novel potentiator is designed as a CFTR...
-
MECHELEN, Belgium and CAMBRIDGE, United Kingdom, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines,...
-
Net profit of €56 M for first half 2014 Solid cash balance of €232 M on 30 June 2014, liquid assets position of €240 M Group revenues €63 M, including...
-
MARTINSRIED / MUNICH, Germany, July 23, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and Galapagos NV (Euronext: GLPG; OTC: GLPYY) announced today that...
-
MECHELEN, Belgium, July 4, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG) announced today a share capital increase arising from warrant exercises. Since its inception in 1999, Galapagos has...
-
Mechelen, Belgium, July 1, 2014 (GLOBE NEWSWIRE) -- Mechelen, Belgium; 1 July 2014 - Galapagos NV (Euronext: GLPG) announced today that GLPG1690, a first-in-class molecule aimed at treating pulmonary...
-
Mechelen, België; 1 juli 2014 - Galapagos NV (Euronext: GLPG) kondigt vandaag aan dat het een klinische Fase 1 trial is gestart met GLPG1690, een middel voor de behandeling van longziekten. ...
-
Mechelen, Belgium; 1 July 2014 - Galapagos NV (Euronext: GLPG) announced today that GLPG1690, a first-in-class molecule aimed at treating pulmonary diseases, has been dosed in a Phase 1...
-
Mechelen, Belgium, April 10, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext:GLPG) announced today a share capital increase arising from warrant exercises. Since its inception in 1999, Galapagos...
-
· Total cash consideration of up to €134 million o €129 million cash payment o earnout of €5 million upon achievement...